Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

BACKGROUND The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. METHODS We conducted a multinational, randomized, double-blind, placebo-controlled phase 3 trial of sunitinib in patients with advanced, well-differentiated pancreatic neuroendocrine tumors. All patients had Response Evaluation Criteria in Solid Tumors-defined disease progression documented within 12 months before baseline. A total of 171 patients were randomly assigned (in a 1:1 ratio) to receive best supportive care with either sunitinib at a dose of 37.5 mg per day or placebo. The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety. RESULTS The study was discontinued early, after the independent data and safety monitoring committee observed more serious adverse events and deaths in the placebo group as well as a difference in progression-free survival favoring sunitinib. Median progression-free survival was 11.4 months in the sunitinib group as compared with 5.5 months in the placebo group (hazard ratio for progression or death, 0.42; 95% confidence interval [CI], 0.26 to 0.66; P<0.001). A Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied. The objective response rate was 9.3% in the sunitinib group versus 0% in the placebo group. At the data cutoff point, 9 deaths were reported in the sunitinib group (10%) versus 21 deaths in the placebo group (25%) (hazard ratio for death, 0.41; 95% CI, 0.19 to 0.89; P=0.02). The most frequent adverse events in the sunitinib group were diarrhea, nausea, vomiting, asthenia, and fatigue. CONCLUSIONS Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors. (Funded by Pfizer; ClinicalTrials.gov number, NCT00428597.).

[1]  U. Knigge,et al.  Interventional treatment of neuroendocrine liver metastases. , 2008, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[2]  J. Blay,et al.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.

[3]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[5]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[6]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[7]  M. Fjällskog,et al.  Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas , 2007, Acta oncologica.

[8]  L. Kvols,et al.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J.,et al.  The New England Journal of Medicine , 2012 .

[10]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  L. Saltz,et al.  Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma , 1999, Cancer.

[12]  L. Sobin,et al.  Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.

[13]  J. Hanley,et al.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. , 1980, The New England journal of medicine.

[14]  C. Schade-Brittinger,et al.  Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group , 2009 .

[15]  Douglas B. Evans,et al.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. H. Dinsmore,et al.  New England , 1894, Letters from America.

[17]  J. Cameron,et al.  Liver Metastases Arising from Well-Differentiated Pancreatic Endocrine Neoplasms Demonstrate Increased VEGF-C Expression , 2003, Modern Pathology.

[18]  U. Harmenberg,et al.  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[21]  L. Tye,et al.  Activity of sunitinib in patients with advanced neuroendocrine tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Wiedenmann,et al.  Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center , 2004, Annals of the New York Academy of Sciences.

[23]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Mills Progress in treatment of cancer of uterine cervix. , 1968, European journal of cancer.

[25]  E. Raymond,et al.  Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer , 2009, Drug safety.

[26]  L. Kvols,et al.  Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma , 2007, Neuroendocrinology.

[27]  I. Modlin,et al.  article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .

[28]  J. Christensen,et al.  78 POSTER Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models , 2006 .

[29]  Y. Bang,et al.  Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. , 2010 .

[30]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[31]  M. Fjällskog,et al.  Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  N. Ballian,et al.  A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[33]  Jeffrey W. Clark,et al.  Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors , 2004, American journal of clinical oncology.

[34]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Lipsitz,et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. , 1992, The New England journal of medicine.

[36]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[38]  Raffaella Barone,et al.  Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[39]  R. Pearson Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2011 .

[40]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Benson,et al.  Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. , 2001, Surgery.

[42]  A. Einstein,et al.  Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.